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MicroRNA-34a upregulation during seizure-induced
neuronal death
T Sano1,2, JP Reynolds1, EM Jimenez-Mateos1, S Matsushima2, W Taki2 and DC Henshall*,1
MicroRNAs (miRNAs) are short, noncoding RNAs that function as posttranscriptional regulators of gene expression by
controlling translation of mRNAs. A subset of miRNAs may be critical for the control of cell death, including the p53-regulated
miRNA, miR-34a. Because seizures activate p53, and p53-deficient mice are reportedly resistant to damage caused by prolonged
seizures, we investigated the role of miR-34a in seizure-induced neuronal death in vivo. Status epilepticus was induced by intra-
amygdala microinjection of kainic acid in mice. This led to an early (2 h) multifold upregulation of miR-34a in the CA3 and CA1
hippocampal subfields and lower protein levels of mitogen-activated kinase kinase kinase 9, a validated miR-34a target.
Immunoprecipitation of the RNA-induced silencing complex component, Argonaute-2, eluted significantly higher levels of miR-
34a after seizures. Injection of mice with pifithrin-a, a putative p53 inhibitor, prevented miR-34a upregulation after seizures.
Intracerebroventricular injection of antagomirs targeting miR-34a reduced hippocampal miR-34a levels and had a small
modulatory effect on apoptosis-associated signaling, but did not prevent hippocampal neuronal death in models of either severe
or moderate severity status epilepticus. Thus, prolonged seizures cause subfield-specific, temporally restricted upregulation of
miR-34a, which may be p53 dependent, but miR-34a is probably not important for seizure-induced neuronal death in this model.
Cell Death and Disease (2012) 3, e287; doi:10.1038/cddis.2012.23; published online 22 March 2012
Subject Category: Neuroscience
MicroRNAs (miRNAs) are an expanding class of small
noncoding RNAs that function as posttranscriptional regula-
tors of gene expression. They are critical for embryogenesis,
development and normal cell physiology.1 miRNAs are
processed from primary transcripts to pre-miRNA, exported
from the nucleus, processed further by Dicer, after which a
single strand is uploaded to the RNA-induced silencing
complex (RISC).2 Here, approximately seven-nucleotide seed
regions within the 50 portion of the miRNA associate with
complementary regions within the 30 untranslated region of
the mRNA, along with additional base pairing, resulting in
translational repression or mRNA decay.3 miRNAs have been
shown to regulate cell cycle and cell death, and miRNA
dysfunction has been implicated in neurodegenerative dis-
eases.4 Acute neurological insults also alter expression of
miRNAs, and emerging data show that prolonged seizures
(status epilepticus (SE)) regulate miRNA expression in the
brain.5–7
The p53 transcription factor is an important regulator of cell
cycle, DNA repair and apoptosis. When activated, p53
transcribes several genes that promote either DNA repair
(e.g., Gadd45a), cell cycle arrest (Cdc25c) or apoptosis
(Puma, Bax).8 Prolonged seizures lead to accumulation of
p53 in the neurons and induction of Puma.9–11 Pharmacolo-
gical or genetic inhibition of p53 or loss of Puma is protective in
in vivo models of seizure-induced neuronal death,11–15
although the genetic background has been shown to be an
important influence on whether p53 deficiency is protective in
seizure models.16
miR-34a belongs to one of several evolutionarily conserved
families of miRNAs and is a p53-regulated miRNA that is
constitutively expressed in the brain.17 Welch et al.18 were the
first to demonstrate pro-apoptotic functions of miR-34a,
followed thereafter by a series of reports confirming and
extending this evidence.19–22 Overexpression of miR-34a was
shown to induce caspase-dependent apoptosis in cells,18
whereas inactivation of miR-34a inhibited p53-dependent
apoptosis.19 Nevertheless, miR-34a may be necessary but
not sufficient to account for p53-dependent apoptosis. miR-
34a may also have p53-independent pro-apoptotic mechan-
isms,20 and miR-34a was recently reported to influence
neuronal morphology and function23 and attenuate p53
regulation of induced pluripotent stem cell generation.24
Several targets of miR-34a have been identified, including
Bcl-2,17 E2F318 and mitogen-activated protein kinase kinase
kinase 9 (MAP3K9; MLK1).25 Overexpression of miR-34a in
cells is capable, however, of altering expression of over 100
proteins.20,26 Thus, the pro-apoptotic mechanism and full
repertoire of miR-34a effects remain to be cataloged.
Given the evidence that p53 contributes to seizure-induced
neuronal death in vivo and emerging data supporting a role for
miRNAs in the pathophysiology of epilepsy, we hypothesized
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that miR-34a would be upregulated by seizures and contribute
to seizure-induced neuronal death. Our results show that
seizures strongly upregulate miR-34a, and that this is p53
regulated, but silencing miR-34a in vivo does not prevent
seizure-induced neuronal death.
Results
Rapid upregulation of miR-34a after SE. We have
previously shown that protein levels of p53 begin to
increase in the cornu ammonis (CA) 3 subfield of the
hippocampus within 1 h of SE.11 As miR-34a is a p53-
regulated miRNA, we examined whether seizures also
upregulate miR-34a. SE was induced by unilateral
microinjection of kainic acid (KA, 1 mg) into the amygdala of
mice, as described earlier.14 Electroencephalogram (EEG)
recordings from skull-mounted electrodes confirmed
seizures, in the form of high-amplitude high-frequency
discharges (HAHFDs), emerging within 5–10 min of KA
injection (Supplementary Figure 1a). Electrographic
seizures continued, becoming near continuous over the
next 40 min. Histopathological inspection of the hippocampus
24 h later revealed seizure-induced neuronal death as
detected by Fluoro-Jade B (FJB) staining within the
ipsilateral CA3 subfield (Supplementary Figure 1b).
Damage to the ipsilateral hilus was also present, along with
lesser injury to area CA1 (Supplementary Figure 1b).
Using real-time (RT)-PCR, we measured expression of
mature miR-34a within the CA3 and CA1 subfields of the
ipsilateral hippocampus at various time points, and compared
levels with samples from time-matched, vehicle-injected non-
seizure controls (Figures 1a and b). A large increase in
miR-34a expression was detected 2 h following SE in the CA3
subfield (Figure 1a). Expression of miR-34a in CA3 returned
to a similar level to controls at 6 and 24 h, and levels of
miR-34a were also not different from that of controls at 3 and 7
days, which corresponds to the time when the first sponta-
neous (i.e., epileptic) seizures occur in the model.11,15
Expression of miR-34a also increased in the less damaged
CA1 subfield after SE, beginning at 2 h but peaking later, at
6 h, and at much higher levels than in CA3 (Figure 1b). Levels
of miR-34a in CA1 were similar to controls at 1, 3 and 7 days
after SE (Figure 1b).
Increased binding of miR-34a to Argonaute-2 after
SE. miRNA function requires their uploading into the RISC,
where Argonuate-2 (Ago-2) contributes to miRNA-induced
silencing of mRNAs.3 To determine whether increased miR-
34a levels after seizures result in a corresponding increased
loading of the miRNA into the RISC, we immunoprecipitated
Ago-2 from control and seizure hippocampus at 2 h and used
PCR to detect miR-34a. Western blot analysis did not detect
a significant difference in Ago-2 levels between controls and
KA-injected mice at 2 h (data not shown). Levels of Ago-2-
bound miR-34a were increased over 3.5-fold in seizure
samples compared with controls (Figure 2a).
We next examined whether a recently experimentally
validated miR-34a target, Map3k9,25 showed the predicted
downregulation at the protein level shortly after the time when
miR-34a was upregulated. Western blot analysis found a
significant reduction in hippocampal Map3k9 protein levels at
2 and 4 h after SE (Figures 2b and c). Map3k9 levels returned
to control levels at 24 h after SE (Figures 2b and c).
miR-34a induction by seizures is blocked by pifithrin-a.
To explore whether miR-34a was under p53 control during
seizure-induced neuronal death, we treated mice with
pifithrin-a, a p53 inhibitor,27 before SE. Seizure severity was
not significantly different between mice injected with pifithrin-a
or vehicle (data not shown). To confirm that pifithrin-a had
blocked p53 transcriptional activity, we measured expression
of p21WAF/Cip1, a known p53-regulated gene encoding a
cyclin-dependent kinase inhibitor.11,19,22 Hippocampal levels
of p21WAF/Cip1 were significantly lower in mice treated with
pifithrin-a (4 mg/kg, twice) before SE compared with vehicle
controls after seizures (Figure 2d).
Next, we measured miR-34a levels in CA3 samples from
vehicle- and pifithrin-a-injected seizure mice. Administration
of pifithrin-a significantly reduced hippocampal miR-34a
expression 2 h after SE relative to vehicle-injected seizure
controls (Figure 2e). To evaluate the specificity of this effect,
we measured miR-92a, which may be under p53 control in
some systems.22 Levels of miR-92a were not reduced in
pifthrin-a-treated mice (P¼ 0.09, data not shown). Similarly,
expression of miR-134, which has not been associated with
Figure 1 SE induces rapid upregulation of miR-34a. (a and b) RT-PCR
measurement of mature miR-34a levels in CA3 and CA1 subfields from control
(Con) mice and animals subjected to SE at various time points. Expression levels
were corrected to RNU6B. *Po0.05 compared with control (n¼ 4 per group)
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p53 regulation, was not reduced by pifithrin-a (P¼ 0.15, data
not shown).
In vivo depletion of miR-34a using antagomirs. We
recently reported that miR-132 expression could be
reduced in vivo by intracerebroventricular (i.c.v.) injection of
sub-nanomolar doses of locked nucleic acid–modified,
cholesterol-tagged antagomirs.7 We therefore used i.c.v.
injections of antagomirs targeting miR-34a (Ant-34a) to
reduce brain levels of miR-34a in vivo. Injection of 0.1 nmol
Ant-34a did not significantly change hippocampal miR-34a
levels when assessed 24 h later relative to a nontargeting
scrambled control (Figure 3a). In contrast, miR-34a levels
were significantly reduced in mice injected with 0.5 nmol Ant-
34a (Figure 3a). Expression of miR-134 was not significantly
altered by injection of either dose of antagomir (Figure 3b).
Further increases of antagomirs/scrambled doses were not
attempted because of possible off-target effects on other
miRNAs above 0.5 nmol.7
We next subjected mice to intra-amygdala KA-induced SE
24 h after i.c.v. injection of 0.5 nmol of either Ant-34a or
scrambled (Figure 3c). Seizure severity as assessed by
durations of HAHFDs or total EEG power analysis was not
significantly different between mice given Ant-34a compared
with scrambled-injected mice (P¼ 0.11 for HAHFDs; P¼ 0.41
for total power, Figures 3c and d).
Inhibition of miR-34a does not prevent seizure-induced
neuronal death in vivo. We next compared damage within
dorsal (septal) hippocampus between Ant-34a- and
scrambled-treated mice 24 h after SE. In rostral sections,
seizure-induced neuronal death in scrambled-injected mice
exhibited typical damage within CA3, hilus and CA1 subfields
(Figure 4a, and compare to Supplementary Figure 1b).
Seizure-induced neuronal death was not different in mice
injected with antagomirs targeting miR-34a (Figures 4a
and b); that is, Ant-34a-injected animals displayed similar
CA3 lesions to scrambled mice, and counts of FJB-positive
Figure 2 RISC loading of miR-34a, downregulation of target Map3k9 and p53
dependence. (a) Graph showing miR-34a levels eluted by immunoprecipitation of
Ago-2 from non-seizure controls (Con) and mice 2 h after SE. ***Po0.001
compared with control (n¼ 3 per group). (b) Representative western blot (n¼ 1 per
lane) showing protein levels of the miR-34a target Map3k9 in Con and 2, 4 or 24 h
after SE. b-Actin is included as a guide to protein loading. Molecular weight markers
depicted to the right. Time in hours after KA is shown above. (c) Semiquantification
of Map3k9 levels after seizures. *Po0.05 compared with control (n¼ 4 per group).
(d) RT-PCR measurement of p53-target gene p21WAF/Cip1 expression in seizure
mice at 2 h showing reduced expression of the p53-regulated gene in mice treated
with pifithrin-a (PFT) compared with vehicle (Veh, DMSO; *Po0.05 compared
with vehicle; n¼ 5 per group). (e) Graph showing RT-PCR measurement of
miR-34a in animals given PFT or Veh before SE. **Po0.01 compared with
vehicle (n¼ 3–4 per group)
Figure 3 Effect of antagomirs on brain levels of miR-34a and seizure EEG.
(a and b) Effect of antagomirs targeting miR-34a (Ant-34a) and scrambled (Scram)
on hippocampal CA3 expression of A, miR-34a, and B, miR-134, measured 24 h
after injection. Expression levels were corrected to RNU6B. *Po0.05 compared
with Scram (n¼ 3 per group). (c) Representative EEG spectrogram during SE in
mice given either Scram or Ant-34a. (d) Graphs showing semiquantification of
seizure parameters between treated mice subjected to SE (n¼ 7–8 per group).
Differences were not statistically significant
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CA3 neurons found no difference between the groups at
this stereotaxic level (Figure 4b). Results were similar when
medial sections were analyzed, with similar distribution of
hippocampal damage and no difference in FJB counts
between the groups (Figures 4a and c). We also stained
additional sections for DNA fragmentation using terminal
deoxynucleotidyl dUTP nick end labeling (TUNEL). TUNEL
counts were not different between scrambled- and
antagomir-treated mice (data not shown).
To exclude the possibility that seizure-induced neuronal
death triggered by 1mg KA was too severe to protect against,
we undertook a second series of experiments in mice given a
lower dose of KA. This produces a focal lesion, mainly within
the CA3 subfield, with only occasional neuronal death in the
hilus.14 Seizure severity was again comparable between mice
injected with scrambled or Ant-34a and then subjected to
seizures by 0.3mg intra-amygdala KA (Figures 5a and b).
Analysis of seizure-induced neuronal death found a typical
CA3-dominant lesion in scrambled-injected mice subjected
to SE via intra-amygdala injection of 0.3mg KA (Figure 5c).
Figure 4 No effect of antagomirs targeting miR-34a on seizure-induced
neuronal death. (a) Representative photomicrographs of the ipsilateral hippocam-
pus at two levels of the dorsal hippocampus from mice 24 h after SE given either
0.5 nmol Scram or Ant-34a. Black dots are FJB-positive cells. Scale bars; rostral,
550mm; medial, 600 mm. (b and c) Graphs showing FJB counts in ipsilateral CA3
and CA1 at rostral and medial levels of the dorsal hippocampus 24 h after SE
(n¼ 7–8 per group). Differences were not statistically significant
Figure 5 Antagomirs targeting miR-34a do not prevent neuronal death caused
by moderate severity SE. (a) Representative seizure EEG spectrogram showing
amplitude and frequency during SE in mice that received either targeting (Ant-34a)
or non-targeting (Scram) antagomirs (0.5 nmol each) 24 h before intra-amygdala
microinjection of 0.3mg KA. Note more delayed emergence and lesser amplitude/
frequency of seizures relative to 1 mg KA model. (b) Graphs showing similar seizure
parameters between Ant-34a and Scram-injected mice subjected to 0.3mg KA-
induced SE (n¼ 3 per group). (c) Representative photomicrographs of the FJB
stained ipsilateral hippocampus at two levels of dorsal hippocampus of mice
24 h after SE induced by 0.3mg KA and given either Scram or Ant-34a. Scale bar,
575mm. (d) Graphs showing FJB counts in ipsilateral CA3 24 h after 0.3mg
KA-induced SE (n¼ 3 per group)
miR-34a and seizures
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Mice injected with Ant-34a also displayed a similar CA3
lesion, and there was no significant difference between
groups (Figures 5c and d).
Modulation of apoptosis signaling pathways following
inhibition of miR-34a. Although inhibition of miR-34a did
not alter seizure-induced neuronal death, we hypothesized
that miR-34a reduction might still have effects on the
signaling pathways underlying apoptosis. Accordingly, we
undertook western blot analysis of proteins from the temporal
portion of the hippocampus of scrambled and Ant-34a mice
24 h after seizures. Levels of the cleaved p19 fragment of
caspase-3, but not p17 fragment, were significantly lower in
samples from mice injected with miR-34a-targeting
antagomirs compared with animals given the scrambled
sequence (Figures 6a and b and data not shown). Levels of
pro-caspase-3 were not different between groups (Figures
6a and b). We also looked at protein levels of Bax because
the mRNA for Bax may contain a potentially complementary
7- to 9-nt seed match for miR-34a (see Materials and
Methods). Levels of full-length Bax were, surprisingly,
significantly higher in antagomir-treated mice than
scrambled animals (Figures 6b and c). Levels of a p18
fragment of Bax, reported to be a more pro-apoptotic
truncated form,28 were also increased in antagomir-injected
mice (Figures 6c and d).
Discussion
In this study, we report that miR-34a is rapidly upregulated in
the hippocampus following experimental SE in mice. Levels of
miR-34a were also increased within the RISC, and a known
target, Map3k9, showed the expected downregulation at a
protein level. Results with pifithrin-a suggest that the control of
miR-34a is p53 dependent. However, reducing miR-34a
expression in vivo using antagomirs failed to alter seizure-
induced neuronal death. These studies identify miR-34a as a
seizure-regulated miRNA, although the in vivo significance of
seizure-induced miR-34a upregulation remains uncertain.
Emerging data point to important roles for miRNAs in the
pathogenesis of seizure-induced neuronal death and epi-
lepsy. Indeed, miRNA profiling has detected expression
changes for multiple miRNAs following experimentally evoked
seizures,6,7 and miRNA regulation in experimental and human
epilepsy.5,29 The in vivo targets and functional significance of
most of these miRNAs remain undetermined, but identifica-
tion of miRNAs regulating seizure-induced neuronal death
could lead to novel targets for neuroprotection and, possibly,
anti-epileptogenesis.7,30 This study explored the role of miR-
34a because it had been implicated in p53-dependent control
of apoptosis.17 We used intra-amygdala microinjection of KA
to trigger focal-onset SE, which produces unilateral hippo-
campal damage and the subsequent emergence of epileptic
seizures.31 Apoptotic pathways contribute to seizure-induced
neuronal death in the model, as evidenced by significantly
altered hippocampal damage in animals lacking apoptosis-
associated genes, including p53, and pharmacological
manipulations of core apoptotic components.11,14,15,32 We
report for the first time that miR-34a is upregulated after SE in
mice. Our data extend earlier profiling work in rats treated with
pilocarpine6 and featured individual RT-PCR measurement of
mature miR-34a levels, subfield-specific information as
opposed to whole hippocampus and a complete temporal
profile. Ago-2 pull-down experiments showed that miR-34a
was uploaded to the RISC where miRNA-based RNA
silencing occurs, and we detected the downregulation
of Map3k9 protein, a miR-34a target.25 Some miRNA
profiling studies did not detect changes to miR-34a in
Figure 6 Modulation of apoptosis-associated signaling after antagomirs targeting miR-34a. (a) Levels of cleaved and full-length (fl) caspase-3 (Casp3) protein in
hippocampal samples from Scram- or Ant-34a-injected mice 24 h after SE (n¼ 8 per group). Protein levels were corrected to b-actin. (b) Representative western blots
(n¼ 1 per lane) showing hippocampal levels of Casp3, p17/19 cleaved Casp3 (cCasp3, arrows) and b-actin as a loading control. (c) Levels of Bax and p18 Bax in each
group (n¼ 8 per group). (d) Representative western blots (n¼ 1 per lane) showing hippocampal levels of Bax and p18 Bax. **Po0.01, *Po0.05 compared with Scram
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seizure models.6,29 This may be because single or later
time point sampling would miss the abrupt induction and
subsequent restitution of miR-34a levels we observed here.
The large-scale upregulation of miR-34a was unexpected,
particularly in CA1, exceeding that reported for the pilocarpine
model.6 The increase is also greater than in most reports
on miR-34a upregulation in non-neuronal tissue.19,21,24
Thus, SE, particularly when induced via intra-amygdala KA,
is a potent inducer of miR-34a.
miR-34a-induced cell death is caspase dependent,18 and
the pro-apoptotic effects of miR-34a may derive from inhi-
biting translation of anti-apoptotic proteins, such as Bcl-2.17
The observed upregulation of miR-34a in CA3 after SE
coincides with the earliest events in the cell death process in
this model and precedes post-mitochondrial events such as
caspase processing.11,32 Although the caspase dependence
of neuronal death in this model has not been tested directly,
the seizure-induced damage is both p53- and Bcl-2 family
protein dependent.11,15,32 The larger and more sustained
increase in miR-34a levels detected in CA1 was unexpected
because the CA1 subfield is less damaged in the model.14,32 If
miR-34a is activity regulated, then it could reflect preserved
function of this neuron population to transcribe the gene
compared with the more damaged CA3. This pattern would
also be consistent with miR-34a functions besides control of
cell death.23,24,33
By comprehensively covering the temporal profile of
miR-34a expression after seizures, we found an unusually
restricted period of induction. It is unknown why miR-34a
levels returned to control in both CA1 and CA3. Indeed, p53
expression remains elevated until at least 24 h in this model.11
Rapid turn-on/turn-off transitions were not noted in the original
work linking miR-34a to p53.19–22 This may be specific,
therefore, to the tissue and model. It is possible that p53
targeting of the miR34a gene after seizures is transient and
specific to the early transcriptional functions of p53 in the cell
death process. Alternatively, p53 may be transcriptionally
active for only short periods in the model, perhaps undertaking
transcription-independent functions later.34
A number of miRNAs have been shown to be regulated in
experimental and human epilepsy.5,29 Here, we looked for
miR-34a regulation in the first week following SE, by which
time epileptic seizures would occur.11,31 Expression of miR-
34a was not upregulated in these mice, consistent with
profiling work in rat experimental epilepsy, which did not find
changes to miR-34a.29 Thus, spontaneous seizures appear
insufficient to induce miR-34a despite p53 being upregulated
in epilepsy.35,36 Taken together, these data suggest that miR-
34a is particularly associated with the early pathological
changes associated with seizure-induced neuronal death but
not epilepsy. This contrasts certain other miRNAs that have
been shown to be regulated both after SE and in chronic
epilepsy.5,29
Our findings with pifithrin-a, an inhibitor of p53,13,27 suggest
that miR-34a upregulation during seizure-induced neuronal
death is under the control of p53. The specificity of this
approach was confirmed by the knockdown of p21, a well-
characterized target of p53 and index of its transcriptional
activity.22 However, pifithrin-a has been found to have anti-
apoptotic effects in p53-deficient cells.37 Although miR-34a is
perhaps the most significant known miRNA under p53
control,17 it is not the only miRNA regulated by p53. Several
other miRNAs identified as p53 regulated19,20,22 are also
regulated after seizures in our model, including miRs -21, -29a
and -132.7 Other factors may also maintain or regulate miR-
34a expression, and recent work has identified p53-indepen-
dent mechanisms of miR-34a control via ELK138 and p73.39
There is strong evidence that miR-34a can promote
apoptosis.17 However, the degree to which miR-34a can
induce apoptosis varies between studies, being as little as a
few percent in some reports19 toB20% in others.20 At present,
we found that reducing miR-34a levels in vivo using
antagomirs did not protect against seizure-induced neuronal
death. We used two models, varying the KA dose to alter the
amount of cell death.14 Although modulating miR-34a can
affect inhibitory currents in neurons,23 seizures were not
affected by miR-34a inhibition in either model. Reducing miR-
34a levels had no noticeable effect on damage, but
antagomirs did cause a small change to apoptosis signaling,
a reduction in cleaved caspase-3, consistent with studies
showing that miR-34a promotes caspase-dependent apopto-
sis.18 The relatively small amount of cleaved caspase-3 in the
scrambled-treated seizure animals is consistent with the
limited apoptotic component in the high-dose KA model.14
Thus, miR-34a inhibition may have affected apoptosis
signaling but below a level capable of influencing neuronal
death. We must also consider that some miR-34a may escape
inactivation by antagomirs, leaving some residual miR-34a in
the target tissue. Unexpectedly, we detected higher levels of
Bax in antagomir-treated animals. This may be an indirect
effect of inhibiting miR-34a,40 or even a nonspecific toxic
effect of antagomirs. The result could also be explained if Bax
is a miR-34a target, as suggested by bioinformatics, although
this requires experimental validation. We might speculate that
higher Bax would exert a pro-apoptotic effect, countering any
potentially protective influence of reduced caspase-3 clea-
vage. Regardless, genetic deletion of Puma, a pro-apoptotic
Bcl-2 family protein under p53 control, is strongly protective in
both models,11,14 demonstrating that the models are capable
of detecting functional contributions of p53-regulated pro-
apoptotic genes to neuronal death. Other processes besides
control of apoptosis have been reported to be regulated by
miR-34a, including neuronal function23 and amygdala-
mediated anxiety-like behavior.33 Indeed, combined proteo-
mics–microarray analysis reveal that miR-34a downregulates
dozens of protein-coding genes and likely influences diverse
processes including metabolism, Wnt signaling and invasion/
migration.26 The recent description of miR-34a-deficient
mice23,24 provides the means to assess the impact of
complete miR-34a deficiency, not achievable with antago-
mirs, which may clarify outstanding questions on the
contribution of miR-34a to neuronal death after seizures
and, perhaps, other neuronal functions.23,33,39
In summary, this study contributes to an emerging focus on
miR-34a in the brain, demonstrating that miR-34a is upregu-
lated by prolonged seizures in vivo. This occurred in a spatio-
temporally specific manner that appears to be p53 regulated.
Studies using antagomirs to reduce miR-34a expression in
vivo suggest, however, that miR-34a is not functionally
significant for seizure-induced neuronal death in this model.
miR-34a and seizures
T Sano et al
6
Cell Death and Disease
Materials and Methods
Animal model. Animal procedures were reviewed and approved by the
Research Ethics Committee of the Royal College of Surgeons in Ireland, under
license from the Department of Health, Dublin, Ireland, and were in accordance with
the European Communities Council Directive (86/609/EEC). Adult male C57BL/6
mice (20–22 g) were obtained from Harlan (Oxon, Bicester, UK) and housed in a
climate-controlled biomedical research facility on a 12 h light/dark cycle with food
and water provided ad libitum. All efforts were made to minimize the number of
animals used, and to avoid pain and suffering. Focal-onset SE was induced by intra-
amygdala stereotaxic microinjection of KA, as described previously.11,14 Briefly,
mice were first anesthetized (5% isoflurane in oxygen; maintenance 1.5–2%) and
placed in a stereotaxic frame. Body temperature was maintained within the normal
physiological range with a rectal thermometer and a feedback-controlled heat pad
(Harvard Apparatus, Kent, UK). Following a midline scalp incision, Bregma was
located. Three partial craniectomies were then performed for placement of skull-
mounted recording screws (Bilaney Consultants, Sevenoaks, Kent, UK). A complete
craniectomy was then drilled for placement of a guide cannula (Coordinates from
Bregma; AP¼0.94 mm, L¼2.85 mm based on a mouse brain stereotaxic
atlas). The cannula and electrode assembly was then fixed with dental cement,
anesthesia was discontinued and the animal was removed from the frame. Next,
mice were placed in an open Perspex box and electrodes connected to a Grass
Comet XL lab-based EEG via swivel a commutator (Bilaney Consultants). Baseline
EEG was recorded and then the animal was lightly restrained while an injection
cannula was lowered 3.75 mm below the brain surface to the basolateral amygdala
nucleus for injection of KA (Sigma-Aldrich Ireland Ltd, Arklow, Ireland). The injected
dose was either 0.3 or 1mg in 0.2ml volume to elicit either a moderate or a prolonged
SE, respectively.14 Non-seizure control mice underwent the same surgical procedures
but received intra-amygdala vehicle (PBS, 0.2ml). The injection cannula was carefully
withdrawn and EEG recordings continued. Following EEG recordings, animals were
disconnected and placed in a warmed recovery chamber until recovery.
Mice were killed 2, 4, 6 and 24 h, or 3 and 7 days, after intra-amygdala
injections. Animals were given a pentobarbital overdose and perfused with ice-cold
saline to remove intravascular blood components. For molecular and biochemical
work, brains were microdissected on ice blocks under a microscope and the
hippocampus subdivided to obtain the CA3- and CA1-enriched portions. For
histology, whole brains were flash-frozen in 2-methylbutane and then sectioned
on a cryostat.
Drug injections. Animals were randomized between treatment groups.
Pifithrin-a (4 mg/kg, intraperitoneal, in DMSO) was given as a double injection,
first 24 h and then 1 h before intra-amygdala KA, as described previously.11 For
i.c.v. injections of antagomirs, mice were affixed with a cannula ipsilateral to the
side of KA injection (coordinates from Bregma: AP¼0.4 mm, L¼1.15 mm,
V¼2.0 mm). Mice received a 2-ml infusion of miR-34a-silencing antagomir
(Exiqon, Vedbaek, Denmark) or scrambled antagomir (0.1 or 0.5 nmol), in artificial
cerebrospinal fluid (Harvard Apparatus).
EEG analysis. EEG was recorded and analyzed using the TWin software. Two
parameters were determined. The duration of high-amplitude (42 baseline),
high-frequency (41 Hz) discharges was manually counted. Automated EEG total
power analysis was also performed, using the LabChart Pro v7 software
(ADInstruments Ltd, Oxford, UK).7
RT-q (quantitative) PCR analysis of miRNA expression. Reverse
transcription for individual qPCRs was carried out as described,7 using 250 ng of
total RNA and the High-Capacity Reverse Transcription Kit (Applied Biosystems,
Paisley, UK). RT-specific primers for mouse miRNAs miR-34a, miR-92a and
miR-134 (Applied Biosystems) were used for all miRNA reverse transcription.
Individual qPCRs were carried out on the 7900HT Fast Realtime System
(Applied Biosystems) using miR-34a-, miR-92a- and miR-134-specific Taqman
miRNA assays (Applied Biosystems). RNU6B was used for normalization of
miRNA expression levels. A relative fold change in expression of the target gene
transcript was determined using the comparative cycle threshold method (2DDCT).
The presence of a potential miR-34a consensus site (7 mer) in the 30 UTR of
the Bax mRNA was established using independent bioinformatic alignment tools
(http://www.microrna.org and http://www.targetscan.org).
Western blotting. Hippocampal CA3 subfields were homogenized in a lysis
buffer, boiled in gel-loading buffer and separated on SDS-PAGE gels. Proteins were
electroporated onto nitrocellulose membranes and incubated with antibodies
against Argonaute-2, Caspase-3 (Cell Signaling Technology, Beverly, MA, USA),
Map3k9 (a gift from R Stallings), b-actin and Bax (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Membranes were then incubated with horseradish peroxidase-
conjugated secondary antibodies (Jackson ImmunoResearch, Plymouth, PA, USA)
and bands visualized using Supersignal West Pico chemiluminescence (Pierce,
Rockford, IL, USA). Images were captured using a Fuji-Film LAS-300 (Fuji,
Sheffield, UK) and densitometry performed using the AlphaEaseFC4.0 gel-scanning
integrated optical density software (Alpha Innotech, San Leandaro, CA, USA).
Immunoprecipitation of Ago-2. The association between miRNAs and
Ago-2 was investigated as described earlier.7 The CA3 subfields from three
individual mice were pooled for each sample and homogenized in 0.7 ml of ice-cold
immunoprecipitation buffer (300 mM NaCL, 5 mM MgCl2, 0.1% NP-40, 50 mM Tris
HCl, pH 7.5). The homogenate was centrifuged at 16 000 g for 15 min at 4 1C and
the supernatant was retained. Antibodies against Ago-2 were added to 400mg of
lysate in a final volume of 1 ml, vortex-mixed and incubated overnight at 4 1C. Next,
20ml of 50% Protein-A/G-agarose beads (Biotechnology) was added for 1 h at 4 1C
and then bead complexes centrifuged at 16 000 g for 15 min at 4 1C. The pellet
was washed in immunoprecipitation buffer, and miRNA was extracted using the
miRNeasy kit (Qiagen, West Sussex, UK). Stem–loop reverse transcription and RT
PCR (Applied Biosystems) was performed as above to semiquantify the expression
of the miRNA.
Histopathology. Cryosections (12 mm) were prepared at the level of either
rostral (AP¼1.58 mm) or medial (AP¼1.82 mm) hippocampus. To assess
neuronal death, sections were stained using FJB. Briefly, tissue sections were
air-dried, postfixed in formalin (10%) and then immersed in 0.006% potassium
permanganate solution. Sections were then rinsed and placed in 0.001%
FJB solution in 0.1% acetic acid (Chemicon Europe Ltd, Chandlers Ford, UK).
Sections were rinsed again, dried, cleared and mounted in DPX (Sigma-Aldrich).
DNA damage was analyzed on fresh-frozen sections using a fluorescein-based
TUNEL technique, according to the manufacturer’s instructions (Promega, Madison,
WI, USA), as described.11 Sections were examined using a Nikon 2000s
epifluorescence microscope (Micron Optical Co. Ltd, Enniscorthy, Ireland) under
Ex/Em wavelengths of 472/520 nm (green) and imaged using a Hamamatsu Orca 285
camera (Micron Optical Co. Ltd). Images were processed using Adobe Photoshop 6.0
(Adobe Systems Software Ireland Limited, Dublin, Ireland). Cell counts were performed
for the entire CA3 subfield, beginning at the border with CA2 through to the end of
CA3c/CA4 within the hilus of the dentate gyrus. Counts were the average of two
adjacent sections assessed by an observer blinded to the experimental group/condition.
Data analysis. All data are presented as mean±S.E.M. Two group
comparisons were made using Student’s t-test, whereas multigroup comparisons
were made using analysis of variance followed by appropriate post hoc testing.
Significance was accepted at Po0.05.
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